These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Omalizumab, an anti-immunoglobulin E antibody: state of the art. Incorvaia C; Mauro M; Russello M; Formigoni C; Riario-Sforza GG; Ridolo E Drug Des Devel Ther; 2014; 8():197-207. PubMed ID: 24532966 [TBL] [Abstract][Full Text] [Related]
4. IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy. Humbert M; Bousquet J; Bachert C; Palomares O; Pfister P; Kottakis I; Jaumont X; Thomsen SF; Papadopoulos NG J Allergy Clin Immunol Pract; 2019; 7(5):1418-1429. PubMed ID: 30928481 [TBL] [Abstract][Full Text] [Related]
5. The use of anti-IgE therapy beyond allergic asthma. Stokes JR; Casale TB J Allergy Clin Immunol Pract; 2015; 3(2):162-6. PubMed ID: 25609342 [TBL] [Abstract][Full Text] [Related]
6. Omalizumab in children with severe allergic disease: a case series. Crisafulli G; Caminiti L; Chiera F; Arasi S; Salzano G; Panasiti I; Barbalace A; Pajno GB Ital J Pediatr; 2019 Jan; 45(1):13. PubMed ID: 30642367 [TBL] [Abstract][Full Text] [Related]
8. Effects of omalizumab in patients with food allergy. Rafi A; Do LT; Katz R; Sheinkopf LE; Simons CW; Klaustermeyer W Allergy Asthma Proc; 2010; 31(1):76-83. PubMed ID: 20167148 [TBL] [Abstract][Full Text] [Related]
9. The use of omalizumab in allergen immunotherapy. Dantzer JA; Wood RA Clin Exp Allergy; 2018 Mar; 48(3):232-240. PubMed ID: 29315922 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of omalizumab in paediatric age: an update of literature data. Matin N; Tabatabaie O; Falsaperla R; Pavone P; Serra A; Cocuzza S; Di Mauro P; Licciardello L; Lubrano R; Vitaliti G J Biol Regul Homeost Agents; 2016; 30(2):579-84. PubMed ID: 27358151 [TBL] [Abstract][Full Text] [Related]
12. Omalizumab: not only for asthma. Ben-Shoshan M Recent Pat Inflamm Allergy Drug Discov; 2008 Nov; 2(3):191-201. PubMed ID: 19076009 [TBL] [Abstract][Full Text] [Related]
13. Qualitative effects of omalizumab on concomitant IgE-mediated disease in a severe asthmatic population: a real life observational study. Cusack RP; Sahadevan A; Lane SJ QJM; 2016 Sep; 109(9):601-4. PubMed ID: 26966102 [TBL] [Abstract][Full Text] [Related]
14. The anti-IgE antibody omalizumab as a probe to investigate the role of IgE in pathology. Mauro M; Incorvaia C; Formigoni C; Elia R; Russello M; Pellegrino D Panminerva Med; 2012 Dec; 54(4):305-12. PubMed ID: 23123583 [TBL] [Abstract][Full Text] [Related]
15. Off-label use of omalizumab in non-asthma conditions: new opportunities. Morjaria JB; Polosa R Expert Rev Respir Med; 2009 Jun; 3(3):299-308. PubMed ID: 20477322 [TBL] [Abstract][Full Text] [Related]
16. [Dermatological implications of omalizumab, an anti-IgE antibody]. Di Lucca-Chrisment J Rev Med Suisse; 2015 Apr; 11(468):779-80, 782-3. PubMed ID: 26021140 [TBL] [Abstract][Full Text] [Related]
17. Anaphylaxis due to progesterone hypersensitivity successfully treated with omalizumab. Heffler E; Fichera S; Nicolosi G; Crimi N J Allergy Clin Immunol Pract; 2017; 5(3):852-854. PubMed ID: 28258855 [No Abstract] [Full Text] [Related]
18. No difference in omalizumab efficacy in patients with asthma by number of asthma-related and allergic comorbidities. Chen M; Choo E; Yoo B; Raut P; Haselkorn T; Pazwash H; Holweg CTJ; Hudes G Ann Allergy Asthma Immunol; 2021 Jun; 126(6):666-673. PubMed ID: 33465457 [TBL] [Abstract][Full Text] [Related]
19. A practical guide for implementing omalizumab therapy for food allergy. Casale TB; Fiocchi A; Greenhawt M J Allergy Clin Immunol; 2024 Jun; 153(6):1510-1517. PubMed ID: 38599291 [TBL] [Abstract][Full Text] [Related]
20. Omalizumab : other indications and unanswered questions. Mankad VS; Burks AW Clin Rev Allergy Immunol; 2005 Aug; 29(1):17-30. PubMed ID: 16222081 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]